Table of Content

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Cancer Monoclonal Antibodies Market, by Region, 2018-2027 (USD Billion)
1.2.2. Cancer Monoclonal Antibodies Market, by Type, 2018-2027 (USD Billion)
1.2.3. Cancer Monoclonal Antibodies Market, by Therapies, 2018-2027 (USD Billion)
1.2.4. Cancer Monoclonal Antibodies Market, by Application, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Cancer Monoclonal Antibodies Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Cancer Monoclonal Antibodies Market Dynamics
3.1. Cancer Monoclonal Antibodies Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Cancer Monoclonal Antibodies Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Cancer Monoclonal Antibodies Market, by Type
5.1. Market Snapshot
5.2. Global Cancer Monoclonal Antibodies Market by Type, Performance - Potential Analysis
5.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Type 2017-2027 (USD Billion)
5.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
5.4.1. Murine Antibodies
5.4.2. Chimeric Antibodies
5.4.3. Humanized Antibodies
Chapter 6. Global Cancer Monoclonal Antibodies Market, by Therapies
6.1. Market Snapshot
6.2. Global Cancer Monoclonal Antibodies Market by Therapies, Performance - Potential Analysis
6.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Therapies 2017-2027 (USD Billion)
6.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
6.4.1. Bevacizumab (Avastin)
6.4.2. Rituximab (Rituxan)
6.4.3. Trastuzumab (Herceptin)
6.4.4. Cetuximab (Erbitux)
6.4.5. Panitumumab (Vectibix)
6.4.6. Others
Chapter 7. Global Cancer Monoclonal Antibodies Market, by Application
7.1. Market Snapshot
7.2. Global Cancer Monoclonal Antibodies Market by Application - Potential Analysis
7.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
7.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
7.4.1. Breast Cancer
7.4.2. Blood Cancer
7.4.3. Liver Cancer
7.4.4. Brain Cancer
7.4.5. Colorectal Cancer
7.4.6. Others
Chapter 8. Global Cancer Monoclonal Antibodies Market, Regional Analysis
8.1. Cancer Monoclonal Antibodies Market, Regional Market Snapshot
8.2. North America Cancer Monoclonal Antibodies Market
8.2.1. U.S. Cancer Monoclonal Antibodies Market
8.2.1.1. Type breakdown estimates & forecasts, 2017-2027
8.2.1.2. Therapies breakdown estimates & forecasts, 2017-2027
8.2.1.3. Application breakdown estimates & forecasts, 2017-2027
8.2.2. Canada Cancer Monoclonal Antibodies Market
8.3. Europe Cancer Monoclonal Antibodies Market Snapshot
8.3.1. U.K. Cancer Monoclonal Antibodies Market
8.3.2. Germany Cancer Monoclonal Antibodies Market
8.3.3. France Cancer Monoclonal Antibodies Market
8.3.4. Spain Cancer Monoclonal Antibodies Market
8.3.5. Italy Cancer Monoclonal Antibodies Market
8.3.6. Rest of Europe Cancer Monoclonal Antibodies Market
8.4. Asia-Pacific Cancer Monoclonal Antibodies Market Snapshot
8.4.1. China Cancer Monoclonal Antibodies Market
8.4.2. India Cancer Monoclonal Antibodies Market
8.4.3. Japan Cancer Monoclonal Antibodies Market
8.4.4. Australia Cancer Monoclonal Antibodies Market
8.4.5. South Korea Cancer Monoclonal Antibodies Market
8.4.6. Rest of Asia Pacific Cancer Monoclonal Antibodies Market
8.5. Latin America Cancer Monoclonal Antibodies Market Snapshot
8.5.1. Brazil Cancer Monoclonal Antibodies Market
8.5.2. Mexico Cancer Monoclonal Antibodies Market
8.6. Rest of The World Cancer Monoclonal Antibodies Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Amgen Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Bristol Myers Squibb Company
9.2.3. Eli Lilly and Company
9.2.4. F. Hoffmann-La Roche Ltd
9.2.5. Genmab AS
9.2.6. GlaxoSmithKline PLC
9.2.7. Johnson & Johnson
9.2.8. Novartis AG
9.2.9. Merck & Co., Inc
9.2.10. Spectrum Pharmaceuticals Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption



List of Figures


FIG 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, KEY TRENDS 2019
FIG 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, GROWTH PROSPECTS 2020-2027
FIG 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, PEST ANALYSIS
FIG 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, REGIONAL SNAPSHOT 2017 & 2027
FIG 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
FIG 16. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
FIG 17. ASIA PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
FIG 18. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
FIG 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, COMPANY MARKET SHARE ANALYSIS (2019)


List of Tables


TABLE 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, REPORT SCOPE
TABLE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY TYPE 2017-2027 (USD BILLION)
TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY THERAPIES 2017-2027 (USD BILLION)
TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY APPLICATION 2017-2027 (USD BILLION)
TABLE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 16. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 17. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 19. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 20. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 22. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 23. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 24. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 25. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 26. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 27. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 28. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 29. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 30. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 31. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 32. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 33. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 34. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 35. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 36. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 37. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 38. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 39. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 40. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 41. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 42. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 43. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 44. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 45. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 46. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 47. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 48. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 49. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 50. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 51. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 52. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 53. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 54. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 55. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
TABLE 56. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
TABLE 57. YEARS CONSIDERED FOR THE STUDY
TABLE 58. EXCHANGE RATES CONSIDERED